A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer, Non-small Lung Cancer
Interventions: DRUG: Docetaxel|DRUG: GDC-0032|DRUG: Paclitaxel
Sponsor: Genentech, Inc.